The DOI matches its Crossref record.
PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
Open accessAbstract
Several studies outlined the sensitivity of 68Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with 18F offers numerous advantages, including improved image resolution, longer half-life, and increased production yields. The aim of this study was to assess the PSA-stratified performance of the 18F-labeled PSMA tracer 18F-DCFPyL and the 68Ga-labeled reference 68Ga-PSMA-HBED-CC. Methods: We examined 191 consecutive patients with biochemical recurrence according to standard acquisition protocols using 18F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or 68Ga-PSMA-HBED-CC (n = 129, 158.9 MBq, 60 min after injection). We determined PSA-stratified sensitivity rates for both tracers and corrected our calculations for Gleason scores using iterative matched-pair analyses. As an orthogonal validation, we directly compared tracer distribution patterns in a separate cohort of 25 patients, sequentially examined with both tracers. Results: After prostatectomy (n = 106), the sensitivity of both tracers was significantly associated with absolute PSA levels (P = 4.3 × 10−3). Sensitivity increased abruptly, when PSA values exceeded 0.5 μg/L (P = 2.4 × 10−5). For a PSA less than 3.5 μg/L, most relapses were diagnosed at a still limited stage (P = 3.4 × 10−6). For a PSA of 0.5–3.5 μg/L, PSA-stratified sensitivity was 88% (15/17) for 18F-DCFPyL and 66% (23/35) for 68Ga-PSMA-HBED-CC. This significant difference was preserved in the Gleason-matched-pair analysis. Outside of this range, sensitivity was comparably low (PSA < 0.5 μg/L) or high (PSA > 3.5 μg/L). After radiotherapy (n = 85), tracer sensitivity was largely PSA-independent. In the 25 patients examined with both tracers, distribution patterns of 18F-DCFPyL and 68Ga-PSMA-HBED-CC were strongly comparable (P = 2.71 × 10−8). However, in 36% of the PSMA-positive patients we detected additional lesions on the 18F-DCFPyL scan (P = 3.7 × 10−2). Conclusion: Our data suggest that 18F-DCFPyL is noninferior to 68Ga-PSMA-HBED-CC, while offering the advantages of 18F labeling. Our results indicate that imaging with 18F-DCFPyL may even exhibit improved sensitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels. Although the standard acquisition protocols, used for 18F-DCFPyL and 68Ga-PSMA-HBED-CC in this study, stipulate different activity doses and tracer uptake times after injection, our findings provide a promising rationale for validation of 18F-DCFPyL in future prospective trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sheikhbahaei, S., Afshar-Oromieh, A., Eiber, M., Solnes, L. B., Javadi, M. S., Ross, A. E., Pienta, K. J., Allaf, M. E., Haberkorn, U., Pomper, M. G., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3780-7 · Cited by 295
Werner, R. A., Bundschuh, R. A., Bundschuh, L., Javadi, M. S., Leal, J. P., Higuchi, T., Pienta, K. J., Buck, A. K., Pomper, M. G., Gorin, M. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217588 · Cited by 55
Jansen, B. H. E., Jansen, R. W., Wondergem, M., Srbljin, S., de Klerk, J. M. H., Lissenberg-Witte, B. I., Vis, A. N., van Moorselaar, R. J. A., Boellaard, R., Hoekstra, O. S., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222513 · Cited by 12
“Indeed, 18FDCFPyL PET/CT revealed enhanced localization of BCR compared with 68Ga-PSMA PET/CT in first clinical analyses (12,13).”
BackgroundMethodInfluential
Metadata
- Authors
- Dietlein, F., Kobe, C., Neubauer, S., Schmidt, M., Stockter, S., Fischer, T., Schomäcker, K., Heidenreich, A., Zlatopolskiy, B. D., Neumaier, B., Drzezga, A., & Dietlein, M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2016-12-01
- Volume
- 58
- Issue
- 6
- Pages
- 947-952
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2558756811
- Cited by
- 180
- References
- 0
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. https://app.cochat.ai/papers/10.2967/jnumed.116.185538
- The paper
- Dietlein, F., Kobe, C., Neubauer, S., Schmidt, M., Stockter, S., Fischer, T., Schomäcker, K., Heidenreich, A., Zlatopolskiy, B. D., Neumaier, B., Drzezga, A., & Dietlein, M. (2017). PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.116.185538
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.